Physician profile
Faride Ramos
NPI 1467721464
$3,314.89
in general payments reported to CMS, 2019-2025
26 companies · $830 in 2025
The $830 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2021: $684 · 2022: $491 · 2023: $268 · 2024: $829 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cerapedics INC. | $718.60 | 2023-2025 | I-Factor Peptide Enhanced Bone Graft |
| Novo Nordisk INC | $430.00 | 2021-2024 | Wegovy |
| Nuvasive, INC. | $294.33 | 2021-2022 | |
| Amgen INC. | $253.38 | 2019-2025 | Otezla, Repatha, Otezla |
| Spinal Simplicity, LLC | $244.58 | 2021 | |
| Lilly USA, LLC | $143.88 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Stryker Corporation | $141.14 | 2024 | |
| Sanofi-Aventis U.S. LLC | $140.44 | 2024-2025 | |
| Heartflow, INC. | $133.90 | 2025 | |
| Osteomed LLC | $126.65 | 2022 | |
| Avanir Pharmaceuticals, INC. | $124.99 | 2019 | |
| Exact Sciences Corporation | $81.12 | 2023-2025 | Cologuard Collection Kit |
| Nalu Medical, INC. | $80.56 | 2021 | |
| Medtronic, INC. | $77.47 | 2024 | Catalyft Pl Expandable Interbody System |
| Astellas Pharma US INC | $63.58 | 2024-2025 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.26 | 2023-2025 | Xifaxan |
| Pfizer INC. | $36.51 | 2019 | |
| Currax Pharmaceuticals LLC | $33.80 | 2022-2024 | Contrave |
| Tela Bio, INC. | $29.53 | 2024 | Ovitex 2s |
| Abbott Laboratories | $23.33 | 2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $21.44 | 2024 | Voquezna |
| Genentech USA, INC. | $20.13 | 2019 | |
| Acella Pharmaceuticals, LLC | $18.59 | 2025 | NP Thyroid 60 |
| Menarini Silicon Biosystems, INC. | $18.18 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.50 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faride Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.